Post-traumatic stress disorder in patients treated for schizophrenia: A cross-sectional study in the psychiatric department of Oujda, Morocco.

The prevalence of post-traumatic stress disorder (PTSD) in the general population is unavoidable and it seems that people who are suffering from severe psychiatric disorders especially schizophrenia, are more vulnerable to traumatic exposure and consequently to post traumatic stress disorder. The present work aims at determining the prevalence and the characteristics of the association between schizophrenia and PTSD since it isn't well known in Morocco. Materials and methods: We conducted a descriptive and analytical cross-sectional study over a period of three months from October 2019 to December 2019 at the Department of Mental Health and Psychiatric Diseases of the University Hospital Center Mohammed VI of Oujda. Results: The number of patients included in our study was 187 and the majority of them were male with a percentage of 76%. Several variables were evaluated. The prevalence of PTSD in the patients included in our study is 14%. In addition, the statistically significant variables were the presence of a stressful event (p = 0,001), the positive schizophrenia symptom score (PANSS P) (p = 0,031), the negative schizophrenia symptom score (PANSS N) (p = 0,005), the general schizophrenia symptom score (PANSS G) (p = 0,021), suicide risk (p < 0,001), and the presence of depression (p = 0,004). Conclusion: The comorbidity schizophrenia-PTSD exists with non-negligible prevalence. The risks of non-diagnosis of this comorbidity could lead to inappropriate treatments, a multiplication of care with no notable clinical improvement, poor therapeutic compliance and the alteration in the patients' quality of life.

A very rare case of priapism under aripiprazole in a patient followed for bipolar disorder: A CARE-compliant report.

INTRODUCTION AND IMPORTANCE: Priapism is a urological emergency characterized by abnormally prolonged, painful and irreducible erection. It occurs without a sexual stimulation and habitually exceeds 6 h. About a half of iatrogenic priapisms are believed to be associated with antipsychotics. Until to date, very few cases of aripiprazole-associated priapism were reported. CASE PRESENTATION: In this case report, we present the clinical findings of a 40-year-old patient that developed priapism after treatment with aripiprazole after his hospitalization for an episode of clinical mania following treatment discontinuation for bipolar I disorder. The management was successful and priapism was resolved spontaneously. CLINICAL DISCUSSION: Despite its low affinity to alpha-1 adrenergic receptors, aripiprazole may be associated with priapism. Several potential factors involved in the pathogenesis of this adverse event have been reported in the literature including history of priapism in a different class of neuroleptics and consumption of psychoactive drugs which are the principal factors found in our case. CONCLUSION: Priapism may occur even during treatment with antipsychotics that have a low affinity to alpha1-adrenergic receptors. All patients on antipsychotics should be informed about the risk of this rare but serious adverse event.

Increase in the vascular residence time of propranolol-loaded nanoparticles coated with heparin.

Propranolol-HCI incorporated nanoparticles prepared with a blend of a polyester and a polycationic polymer and coated or not with a low molecular weight heparin by electrostatic interactions were prepared by emulsification followed by solvent evaporation. The mean diameter was 388 and 357 nm for coated and uncoated nanoparticles, respectively, and the entrapment efficiency ranged from 20 to 32%. Coated nanoparticles were negatively-charged, whereas uncoated nanoparticles displayed a positive zeta potential (+30 mV). After intravenous administration to rabbits of propranolol-HCI solution and propranolol-loaded nanoparticles coated or not with heparin, pharmacokinetic data revealed that coated nanoparticles exhibited a prolonged blood residence time. It can be concluded that the hydrophilic layer of heparin at the surface of nanoparticles conferred stealth properties which probably reduce the phagocytosis process and avoid immediate uptake by the mononuclear phagocytic system.

Influence of polymers on the bioavailability of microencapsulated celecoxib.

Celecoxib, a selective COX-2 inhibitor, primarily used in treatment of osteoarthritis, rheumatoid arthritis and acute pain was encapsulated in microparticles composed of various polyesters, polymethacrylates or cellulose derivatives used alone or blended. The influence of polymers on microparticle mean diameter, encapsulation efficiency and in vitro and in vivo celecoxib release was investigated. Microparticles were in the size range 11-37 microm. Encapsulation efficiency was optimal due to poor aqueous solubility of celecoxib. Considering in vitro release, microparticles could be divided into drug delivery systems with fast and slow release profiles. Microparticles prepared with poly-epsilon-caprolactone, Eudragit RS and low viscosity ethylcellulose, together with physical mixture of celecoxib with lactose and Celebrex, were tested in vivo. Relative bioavailability of celecoxib was below 20% in all cases and was probably the consequence of a slow in vivo release of celecoxib from microparticles or low wettability in the case of Celebrex and physical mixture.